- Global Pharma News & Resources

Digipath's Chief Science Officer is featured in the current issue of The Analytical Scientist

LAS VEGAS, Aug. 28, 2018 /PRNewswire/ -- Digipath, Inc. (OTCQB: DIGP), an independent cannabis testing laboratory and media firm, is pleased to announce that its Chief Science Officer, Dr. Cindy Orser, is featured in the current issue of The Analytical Scientist, a publication that celebrates the people, the technology and the innovations that shape Analytical Science across all fields.

In this article, entitled "Smashing the Grass Ceiling," Dr. Orser is one of seven women who are interviewed as breaking the proverbial "glass ceiling" in cannabis science by rising to the top in their perspective companies while other scientific fields still struggle with equity. The feature article can be found online here:

Each female scientist shares their personal story of how they ended up entering cannabis, what is their passion that keeps them motivated in cannabis science and also their personal take on why there seems to be an equitable number of dedicated women scientists working on cannabis. Dr. Orser shared that, "I would like to streamline the required testing for cannabis – Nevada has the most rigorous testing requirements of any state, and there is some overlap in the tests we have to carry out," and "there is a high proportion of female scientists in significant roles in the cannabis industry because the industry was so new, there wasn't time for male domination – it was a level playing field, and there were a lot of mature, well-educated, capable women scientists who saw the opportunity and seized it."

It is definitely an interesting read and quite inspiring for younger women looking to become a cannabis scientist. Todd Denkin, CEO of Digipath said, "At Digipath labs in Las Vegas we have six female scientists including two PhDs and we hope to make it a training ground for more female cannabis scientists as we expand to other markets."

About Digipath, Inc. (OTCQB: DIGP)

Digipath, Inc., supports the cannabis industry's best practices for reliable testing, cannabis education and training, and brings unbiased cannabis news coverage to the cannabis industry.

Digipath Labs provides pharmaceutical-grade analysis and testing to the cannabis industry to ensure producers, consumers and patients know exactly what is in the cannabis they ingest and to help maximize the quality of its client's products through analysis, research, development, and standardization.

Information about Forward-Looking Statements

This press release contains "forward-looking statements" that include information relating to future events. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to: the Company's need for additional funding, the demand for the Company's products, governmental regulation of the cannabis industry, the Company's ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company's liquidity and financial strength to support its growth, and other risks that may be detailed from time-to-time in the Company's filings with the United States Securities and Exchange Commission. For a more detailed description of the risk factors and uncertainties affecting Digipath, please refer to the Company's recent Securities and Exchange Commission filings, which are available at The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.


Investor Relations

Digipath, Inc.

(702) 527.2060

Editor Details

Related Links

Last Updated: 29-Aug-2018